WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc., a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, today announced that the company will present new preclinical data at the Cambridge Healthtech Institute’s Second Annual RNA Interference: From Tools to Therapies Conference, as part of Cambridge Healthtech Institute’s 17th International Molecular Medicine Tri-Conference 2010. The conference is being held February 3-5, 2010 at the Moscone North Convention Center in San Francisco.
